A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.
BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the ...
Key Takeaways Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.The drugmaker said the twice-daily pill, Journavx, is the first such treatment to ...
Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...